About Melt Pharmaceuticals
Melt Pharmaceuticals is a company based in United States founded in 2018, and was acquired by Harrow in September 2025. Pharmaceutical solutions are developed by Melt Pharmaceuticals in the US. Melt Pharmaceuticals has raised $77.29 million across 3 funding rounds from investors including Harrow. Melt Pharmaceuticals offers products and services including MELT-300 and Combination Drug Formulations. Its legal entity is Melt Pharmaceuticals, Inc.
Company details
Melt Pharmaceuticals was founded in 2018 and is headquartered in the United States. Operations are centered in the pharmaceutical sector, though specific services and products remain undisclosed in available records. The companys domain, meltpharma.com, serves as its online presence. Limited public data exists on detailed activities, with focus inferred on drug development or related innovations typical to the industry.
- Headquarters United States
- Stage Acquired
- Website meltpharma.com
- Social LinkedIn
- Acquired by Harrow (Sep 2025)
- Legal Name Melt Pharmaceuticals, Inc
Products & Services of Melt Pharmaceuticals
Melt Pharmaceuticals offers a comprehensive portfolio of products and services, including MELT-300 and Combination Drug Formulations.
A sublingual tablet is developed for needle- and opioid-free procedural sedation and analgesia in short-duration medical procedures
Non-intravenous and non-opioid sedation formulations are created to address sedation needs in outpatient settings
Funding Insights of Melt Pharmaceuticals
Melt Pharmaceuticals has successfully raised a total of $77.29M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $24 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $77.29M
- Total Rounds 3
- Last Round Series B — $24M
- First Round $11M
(Feb 2019)
All 3 funding rounds of Melt Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $24M | Series B | – | – | – |
| Jul 2023 | $42.29M | Series B | – | – | – |
| Feb 2019 | $11M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Melt Pharmaceuticals
Melt Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include Harrow.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic products marketing services are provided by Harrow. | 2012 | harrow.com | Nashville, United States |
Investor details for Melt Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Melt Pharmaceuticals
5 people are tracked at Melt Pharmaceuticals (2 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Brad Osborne | Chief Financial Officer | Leadership |
Larry Dillaha | CEO & Director | Leadership |
Andy Corley | Director | Board & advisors |
Arthur Laffer | Director | Board & advisors |
John Berdahl | Director | Board & advisors |
Complete people profiles for Melt Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Melt Pharmaceuticals
4 dated milestones of Melt Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Melt Pharmaceuticals is founded.
- Funding First funding round of $11.0M.
- Funding Latest funding round, Series B, of $24.0M.
- Exit Acquired by Harrow.
Web traffic of Melt Pharmaceuticals
The website of Melt Pharmaceuticals (meltpharma.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 1.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Melt Pharmaceuticals
Melt Pharmaceuticals was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Melt Pharmaceuticals is headquartered in United States.
Melt Pharmaceuticals is a funded company, having raised a total of $77.29M across 3 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Feb 2019.
Melt Pharmaceuticals was founded in 2018 and is headquartered in the United States. Operations are centered in the pharmaceutical sector, though specific services and products remain undisclosed in available records. The companys domain, meltpharma.com, serves as its online presence. Limited public data exists on detailed activities, with focus inferred on drug development or related innovations typical to the industry.
Melt Pharmaceuticals offers MELT-300 and Combination Drug Formulations.
Melt Pharmaceuticals has 1 investor. Key investors include Harrow.
Melt Pharmaceuticals operates through Melt Pharmaceuticals, Inc.
Yes. Melt Pharmaceuticals was acquired by Harrow in September 2025.